178 related articles for article (PubMed ID: 27771247)
21. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
[TBL] [Abstract][Full Text] [Related]
22. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
[TBL] [Abstract][Full Text] [Related]
23. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
Paiva C; Godbersen JC; Rowland T; Danilova OV; Danes C; Berger A; Danilov AV
Oncotarget; 2017 Mar; 8(13):21128-21139. PubMed ID: 28177892
[TBL] [Abstract][Full Text] [Related]
24. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
25. NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.
Liu X; Jiang Y; Wu J; Zhang W; Liang Y; Jia L; Yu J; Jeong LS; Li L
Biochem Biophys Res Commun; 2017 Jun; 488(1):1-5. PubMed ID: 28450112
[TBL] [Abstract][Full Text] [Related]
26. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
[TBL] [Abstract][Full Text] [Related]
27. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
[TBL] [Abstract][Full Text] [Related]
29. Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.
Chen P; Hu T; Liang Y; Jiang Y; Pan Y; Li C; Zhang P; Wei D; Li P; Jeong LS; Chu Y; Qi H; Yang M; Hoffman RM; Dong Z; Jia L
Oncotarget; 2015 Apr; 6(11):9002-17. PubMed ID: 25797246
[TBL] [Abstract][Full Text] [Related]
30. The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.
Zhang W; Liang Y; Li L; Wang X; Yan Z; Dong C; Zeng MS; Zhong Q; Liu XK; Yu J; Sun S; Liu X; Kang J; Zhao H; Jeong LS; Zhang Y; Jia L
Cell Prolif; 2019 Mar; 52(2):e12536. PubMed ID: 30341788
[TBL] [Abstract][Full Text] [Related]
31. Phase I study assessing the mass balance, pharmacokinetics, and excretion of [
Zhou X; Sedarati F; Faller DV; Zhao D; Faessel HM; Chowdhury S; Bolleddula J; Li Y; Venkatakrishnan K; Papai Z
Invest New Drugs; 2021 Apr; 39(2):488-498. PubMed ID: 33089874
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
[TBL] [Abstract][Full Text] [Related]
33. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
[TBL] [Abstract][Full Text] [Related]
34. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
Nawrocki ST; Griffin P; Kelly KR; Carew JS
Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
[TBL] [Abstract][Full Text] [Related]
35. The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia.
Han K; Wang Q; Cao H; Qiu G; Cao J; Li X; Wang J; Shen B; Zhang J
Oncotarget; 2016 Apr; 7(17):23812-24. PubMed ID: 26993774
[TBL] [Abstract][Full Text] [Related]
36. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.
Yang D; Tan M; Wang G; Sun Y
PLoS One; 2012; 7(3):e34079. PubMed ID: 22457814
[TBL] [Abstract][Full Text] [Related]
37. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells.
Zhang Y; Shi C; Yin L; Zhou W; Wang H; Seng J; Li W
Exp Cell Res; 2017 Sep; 358(2):234-241. PubMed ID: 28663057
[TBL] [Abstract][Full Text] [Related]
39. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
40. Radiosensitization of Human Colorectal Cancer Cells by MLN4924: An Inhibitor of NEDD8-Activating Enzyme.
Wan J; Zhu J; Li G; Zhang Z
Technol Cancer Res Treat; 2016 Aug; 15(4):527-34. PubMed ID: 26082455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
